Zydus Cadila receives tentative approval from the USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

Zydus Cadila has received tentative approval from the USFDA to market Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg (US RLD: TRuvADA® Tablets). Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are used with other HIV medications to help control HIV infection. This product is a combination of two different drugs: Emtricitabine and Tenofovir Disoproxil Fumarate and helps to decrease the amount of HIV in the body so that the immune system can work better.

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 312 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.420 as compared to the previous close of Rs. 431.4. The total number of shares traded during the day was 139711 in over 2974 trades.

The stock hit an intraday high of Rs. 431.9 and intraday low of 418. The net turnover during the day was Rs. 59084163.

Source : Equity Bulls

Keywords